ASCO: Kite's CAR T-Cell therapy Tecartus shows strong overall survival rates

Kite, a subsidiary of US biotech major Gilead Sciences (Nasdaq: GILD), over the weekend announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

The three-year follow-up of ZUMA-2, a Phase II global, multicenter study evaluating the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), and two-year follow-up of ZUMA-3, a global, multi-centre, single-arm, open-label Phase I/II study evaluating brexucabtagene autoleucel in adult patients (≥18 years old) with  R/R B-cell acute lymphoblastic leukemia (B-ALL) were both presented Sunday during a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Three-year follow-up data from ZUMA-2 were also simultaneously published in ASCO’s  Journal of Clinical Oncology.

“We are very encouraged by the totality of these data, which suggest a significant and sustained response with brexucabtagene autoleucel for people living with difficult-to-treat blood cancers like MCL and B-ALL,” said Dr Frank Neumann, senior vice president and global head of clinical development, at Kite. “These longer-term results add to the growing maturity of data on Kite’s CAR T-cell therapies,” he noted.